Combined Diffusion Tensor Imaging and Apparent Transverse Relaxation Rate Differentiate Parkinson Disease and Atypical Parkinsonism

REFERENCES

1. 1.↵
   2. Hughes AJ,
   3. Daniel SE,
   4. Ben-Shlomo Y, et al

   . The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861–70 doi:10.1093/brain/awf080 pmid:11912118

   Abstract/FREE Full Text
2. 2.↵
   2. Joutsa J,
   3. Gardberg M,
   4. Röyttä M, et al

   . Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord 2014;20:840–44 doi:10.1016/j.parkreldis.2014.04.019 pmid:24816002

   CrossRefPubMed
3. 3.↵
   2. Fearnley JM,
   3. Lees AJ

   . Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(pt 5):2283–301 doi:10.1093/brain/114.5.2283 pmid:1933245

   Abstract/FREE Full Text
4. 4.↵
   2. Cykowski MD,
   3. Coon EA,
   4. Powell SZ, et al

   . Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain 2015;138:2293–309 doi:10.1093/brain/awv114 pmid:25981961

   Abstract/FREE Full Text
5. 5.↵
   2. Padovani A,
   3. Borroni B,
   4. Brambati SM, et al

   . Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2006;77:457–63 doi:10.1136/jnnp.2005.075713 pmid:16306152

   Abstract/FREE Full Text
6. 6.↵
   2. Dickson DW,
   3. Rademakers R,
   4. Hutton ML

   . Progressive supranuclear palsy: pathology and genetics. Brain Pathol 2007;17:74–82 doi:10.1111/j.1750-3639.2007.00054.x pmid:17493041

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Blain CR,
   3. Barker GJ,
   4. Jarosz JM, et al

   . Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. Neurology 2006;67:2199–205 doi:10.1212/01.wnl.0000249307.59950.f8 pmid:17190944

   Abstract/FREE Full Text
8. 8.↵
   2. Nicoletti G,
   3. Rizzo G,
   4. Barbagallo G, et al

   . Diffusivity of cerebellar hemispheres enables discrimination of cerebellar or parkinsonian multiple system atrophy from progressive supranuclear palsy-Richardson syndrome and Parkinson disease. Radiology 2013;267:843–50 doi:10.1148/radiol.12120364 pmid:23329659

   CrossRefPubMed
9. 9.↵
   2. Prodoehl J,
   3. Li H,
   4. Planetta PJ, et al

   . Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord 2013;28:1816–22 doi:10.1002/mds.25491 pmid:23674400

   CrossRefPubMed
10. 10.↵
    2. Focke NK,
    3. Helms G,
    4. Pantel PM, et al

    . Differentiation of typical and atypical Parkinson syndromes by quantitative MR imaging. AJNR Am J Neuroradiol 2011;32:2087–92 doi:10.3174/ajnr.A2865 pmid:21998102

    Abstract/FREE Full Text
11. 11.↵
    2. Lee JH,
    3. Han YH,
    4. Kang BM, et al

    . Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy. J Neurol 2013;260:2094–101 doi:10.1007/s00415-013-6951-x pmid:23670309

    CrossRefPubMed
12. 12.↵
    2. Barbagallo G,
    3. Sierra-Peña M,
    4. Nemmi F, et al

    . Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord 2016;31:325–34 doi:10.1002/mds.26471 pmid:26676922

    CrossRefPubMed
13. 13.↵
    2. Planetta PJ,
    3. Ofori E,
    4. Pasternak O, et al

    . Free-water imaging in Parkinson's disease and atypical parkinsonism. Brain 2016;139(pt 2):495–508 doi:10.1093/brain/awv361 pmid:26705348

    Abstract/FREE Full Text
14. 14.↵
    2. Péran P,
    3. Cherubini A,
    4. Assogna F, et al

    . Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133:3423–33 doi:10.1093/brain/awq212 pmid:20736190

    Abstract/FREE Full Text
15. 15.↵
    2. Du G,
    3. Lewis MM,
    4. Styner M, et al

    . Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011;26:1627–32 doi:10.1002/mds.23643 pmid:21618607

    CrossRefPubMed
16. 16.↵
    2. Hughes AJ,
    3. Daniel SE,
    4. Kilford L, et al

    . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–84 doi:10.1136/jnnp.55.3.181 pmid:1564476

    Abstract/FREE Full Text
17. 17.↵
    2. Gilman S,
    3. Wenning GK,
    4. Low PA, et al

    . Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670–76 doi:10.1212/01.wnl.0000324625.00404.15 pmid:18725592

    Abstract/FREE Full Text
18. 18.↵
    2. Litvan I,
    3. Agid Y,
    4. Calne D, et al

    . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9 doi:10.1212/WNL.47.1.1 pmid:8710059

    Abstract/FREE Full Text
19. 19.↵
    2. Nasreddine ZS,
    3. Phillips NA,
    4. Bédirian V, et al

    . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–99 doi:10.1111/j.1532-5415.2005.53221.x pmid:15817019

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Avants BB,
    3. Tustison NJ,
    4. Song G, et al

    . A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 2011;54:2033–44 doi:10.1016/j.neuroimage.2010.09.025 pmid:20851191

    CrossRefPubMed
21. 21.↵
    2. Wang J,
    3. Vachet C,
    4. Rumple A, et al

    . Multi-atlas segmentation of subcortical brain structures via the AutoSeg software pipeline. Front Neuroinform 2014;8:7 doi:10.3389/fninf.2014.00007 pmid:24567717

    CrossRefPubMed
22. 22.↵
    2. Avants BB,
    3. Yushkevich P,
    4. Pluta J, et al

    . The optimal template effect in hippocampus studies of diseased populations. Neuroimage 2010;49:2457–66 doi:10.1016/j.neuroimage.2009.09.062 pmid:19818860

    CrossRefPubMed
23. 23.↵
    2. Avants BB,
    3. Epstein CL,
    4. Grossman M, et al

    . Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 2008;12:26–41 doi:10.1016/j.media.2007.06.004 pmid:17659998

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Cawley GC,
    3. Talbot NL

    . On over-fitting in model selection and subsequent selection bias in performance evaluation. J Mach Learn Res 2010;11:2079–107
25. 25.↵
    2. Venkatraman ES

    . A permutation test to compare receiver operating characteristic curves. Biometrics 2000;56:1134–38 doi:10.1111/j.0006-341X.2000.01134.x pmid:11129471

    CrossRefPubMed
26. 26.↵
    2. Friedman J,
    3. Hastie T,
    4. Tibshirani R

    . Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010;33:1–22 pmid:20808728

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Robin X,
    3. Turck N,
    4. Hainard A, et al

    . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77 doi:10.1186/1471-2105-12-77 pmid:21414208

    CrossRefPubMed
28. 28.↵
    2. Vaillancourt DE,
    3. Spraker MB,
    4. Prodoehl J, et al

    . High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378–84 doi:10.1212/01.wnl.0000340982.01727.6e pmid:19129507

    Abstract/FREE Full Text
29. 29.↵
    2. Du G,
    3. Lewis MM,
    4. Sen S, et al

    . Imaging nigral pathology and clinical progression in Parkinson's disease. Mov Disord 2012;27:1636–43 doi:10.1002/mds.25182 pmid:23008179

    CrossRefPubMed
30. 30.↵
    2. Schwarz ST,
    3. Abaei M,
    4. Gontu V, et al

    . Diffusion tensor imaging of nigral degeneration in Parkinson's disease: a region-of-interest and voxel-based study at 3 T and systematic review with meta-analysis. Neuroimage Clin 2013;3:481–88 doi:10.1016/j.nicl.2013.10.006 pmid:24273730

    CrossRefPubMed
31. 31.↵
    2. Lewis MM,
    3. Du G,
    4. Kidacki M, et al

    . Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiol Aging 2013;34:1497–503 doi:10.1016/j.neurobiolaging.2012.10.025 pmid:23177595

    CrossRefPubMed
32. 32.↵
    2. He N,
    3. Ling H,
    4. Ding B, et al

    . Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. Hum Brain Mapp 2015;36:4407–20 doi:10.1002/hbm.22928 pmid:26249218

    CrossRefPubMed
33. 33.↵
    2. Schocke MF,
    3. Seppi K,
    4. Esterhammer R, et al

    . Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575–80 doi:10.1212/WNL.58.4.575 pmid:11865135

    Abstract/FREE Full Text
34. 34.↵
    2. Tsukamoto K,
    3. Matsusue E,
    4. Kanasaki Y, et al

    . Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging. Neuroradiology 2012;54:947–55 doi:10.1007/s00234-012-1009-9 pmid:22274571

    CrossRefPubMed
35. 35.↵
    2. Seppi K,
    3. Schocke MF,
    4. Esterhammer R, et al

    . Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922–27 doi:10.1212/01.WNL.0000049911.91657.9D pmid:12654954

    Abstract/FREE Full Text
36. 36.↵
    2. Salvesen L,
    3. Ullerup BH,
    4. Sunay FB, et al

    . Changes in total cell numbers of the basal ganglia in patients with multiple system atrophy: a stereological study. Neurobiol Dis 2015;74:104–13 doi:10.1016/j.nbd.2014.11.008 pmid:25449905

    CrossRefPubMed
37. 37.↵
    2. Betts MJ,
    3. Acosta-Cabronero J,
    4. Cardenas-Blanco A, et al

    . High-resolution characterisation of the aging brain using simultaneous quantitative susceptibility mapping (QSM) and R2* measurements at 7T. Neuroimage 2016;138:43–63 doi:10.1016/j.neuroimage.2016.05.024 pmid:27181761

    CrossRefPubMed
38. 38.↵
    2. Minnerop M,
    3. Specht K,
    4. Ruhlmann J, et al

    . Voxel-based morphometry and voxel-based relaxometry in multiple system atrophy-a comparison between clinical subtypes and correlations with clinical parameters. Neuroimage 2007;36:1086–95 doi:10.1016/j.neuroimage.2007.04.028 pmid:17512219

    CrossRefPubMed
39. 39.↵
    2. Rizzo G,
    3. Martinelli P,
    4. Manners D, et al

    . Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 2008;131:2690–700 doi:10.1093/brain/awn195 pmid:18819991

    Abstract/FREE Full Text
40. 40.↵
    2. Zanigni S,
    3. Calandra-Buonaura G,
    4. Manners DN, et al

    . Accuracy of MR markers for differentiating progressive supranuclear palsy from Parkinson's disease. Neuroimage Clin 2016;11:736–42 doi:10.1016/j.nicl.2016.05.016 pmid:27330973

    CrossRefPubMed
41. 41.↵
    2. Stutzbach LD,
    3. Xie SX,
    4. Naj AC, et al

    . The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathol Commun 2013;1:31 doi:10.1186/2051-5960-1-31 pmid:24252572

    CrossRefPubMed
42. 42.↵
    2. Dickson DW

    . Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2012;2:a009258 pmid:22908195

    Abstract/FREE Full Text
43. 43.↵
    2. Agosta F,
    3. Pievani M,
    4. Svetel M, et al

    . Diffusion tensor MRI contributes to differentiate Richardson's syndrome from PSP-parkinsonism. Neurobiol Aging 2012;33:2817–26 doi:10.1016/j.neurobiolaging.2012.02.002 pmid:22418735

    CrossRefPubMed
44. 44.↵
    2. Boelmans K,
    3. Holst B,
    4. Hackius M, et al

    . Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2012;27:421–27 doi:10.1002/mds.24926 pmid:22290788

    CrossRefPubMed
45. 45.↵
    2. Massey LA,
    3. Jäger HR,
    4. Paviour DC, et al

    . The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology 2013;80:1856–61 doi:10.1212/WNL.0b013e318292a2d2 pmid:23616165

    Abstract/FREE Full Text
46. 46.↵
    2. Focke NK,
    3. Helms G,
    4. Scheewe S, et al

    . Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls. Hum Brain Mapp 2011;32:1905–15 doi:10.1002/hbm.21161 pmid:21246668

    CrossRefPubMed
47. 47.↵
    2. Buchman AS,
    3. Leurgans SE,
    4. Yu L, et al

    . Incident parkinsonism in older adults without Parkinson disease. Neurology 2016;87:1036–44 doi:10.1212/WNL.0000000000003059 pmid:27488597

    Abstract/FREE Full Text
48. 48.↵
    2. Wang Y,
    3. Liu T

    . Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker. Magn Reson Med 2015;73:82–101 doi:10.1002/mrm.25358 pmid:25044035

    CrossRefPubMed
49. 49.↵
    2. Ofori E,
    3. Pasternak O,
    4. Planetta PJ, et al

    . Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. Neurobiol Aging 2015;36:1097–104 doi:10.1016/j.neurobiolaging.2014.10.029 pmid:25467638

    CrossRefPubMed
50. 50.↵
    2. Massey LA,
    3. Micallef C,
    4. Paviour DC, et al

    . Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 2012;27:1754–62 doi:10.1002/mds.24968 pmid:22488922

    CrossRefPubMed
51. 51.↵
    2. Reiter E,
    3. Mueller C,
    4. Pinter B, et al

    . Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov Disord 2015;30:1068–76 doi:10.1002/mds.26171 pmid:25773707

    CrossRefPubMed
52. 52.↵
    2. Scherfler C,
    3. Göbel G,
    4. Müller C, et al

    . Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. Neurology 2016;86:1242–49 doi:10.1212/WNL.0000000000002518 pmid:26935895

    Abstract/FREE Full Text